hLAG3/hPD-1(BALB/c)
Nomenclature
BALB/cJSmo-Pdcd1tm1(hPDCD1)Lag3tm1(hLAG3)Smoc
Cat. NO.
NM-XA-242014
Strain State
Repository Live
Model Description
Validation Data
Fig.1 Detection of PD-1 expression on CD4+ T cells and Tregs in spleen of hLAG3/hPD-1(BALB/cSmoc) mice by FACS. Mice were administred Con A (12.5 mg/kg) by intravenous injection. At 18 h post injection, spleen was collected from the wild-type mouse (male, 7 weeks old) and homozygous hLAG3/hPD-1(BALB/cSmoc) mice (male, 7 weeks old), and analyzed by flow cytometry with anti-mPD-1 and anti-hPD-1.
Abbr. HO, homozygous; WT, wild type.
Fig.2 Detection of LAG3 expression on T cells in spleen of WT BALB/c mice and HO hPD-1/hLAG3(BALB/cSmoc) mice by FACS. Mice were administred Con A (12.5 mg/kg) by intravenous injection. At 18 h post injection, splenocytes were collected from the wild-type mouse (male, 11 weeks old) and homozygous hPD-1/hLAG3(BALB/cSmoc) mice (male, 11 weeks old), and analyzed by flow cytometry with anti-mLAG3 and anti-hLAG3. Human LAG3 was exclusively detectable on T cells from hPD-1/hLAG3(BALB/cSmoc) mice but not on those cells from WT mice. In contrast, mouse LAG3 was exclusively detectable on WT mice but not in hPD-1/hLAG3(BALB/cSmoc) mice.
Abbr. HO, homozygous; WT, wild type.
Fig.3 Detection of LAG3 expression on CD4+T cells in spleen of WT BALB/c mice and HO hPD-1/hLAG3(BALB/cSmoc) mice by FACS. Mice were administred Con A (12.5 mg/kg) by intravenous injection. At 18 h post injection, splenocytes were collected from the wild-type mouse (male, 11 weeks old) and homozygous hPD-1/hLAG3(BALB/cSmoc) mice (male, 11 weeks old), and analyzed by flow cytometry with anti-mLAG3 and anti-hLAG3. Human LAG3 was exclusively detectable on CD4+ and CD8+ T cells from hPD-1/hLAG3(BALB/cSmoc) mice but not on those cells from WT mice. In contrast, mouse LAG3 was exclusively detectable on WT mice but not in hPD-1/hLAG3(BALB/cSmoc) mice.
Abbr. HO, homozygous; WT, wild type.
Fig.4 In vivo efficacy of Relatlimab plus Nivolumab in hLAG3/hPD-1(BALB/cSmoc) mice. Means of tumor volume(A) and body weight(B). Female, 10-13-week-old homozygous hLAG3/hPD-1(BALB/cSmoc) mice were inoculated subcutaneously in the right flank with CT26 tumor cells (1×106 cells) and grouped when the mean tumor size reaches approximately 100 mm3. Mice received PBS (Group 1), Nivolumab (Group 2, 1 mg/kg) and Relatlimab plus Nivolumab (Group 3, 10 mg/kg Relatlimab and 1 mg/kg Nivolumab) intraperitoneal injection. The tumor volume and body weight were measured twice a week.(n=6, Mean±SEM, t-test, * p < 0.05, ns, no significance).
Table 1. Blood routine examination of HO hLAG3/hPD-1(BALB/c) mice. The baseline physiological parameters of HO hLAG3/hPD-1(BALB/c) mice showed no significant abnormalities.Abbr. HO, homozygous; WT, wild type. Values are expressed as mean±SD.
Table 2. Biochemical test of serum from HO hLAG3/hPD-1(BALB/c) mice. Abbr. HO, homozygous; WT, wild type. Values are expressed as mean±SD.
You may also like
Workshop：Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn moreShanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
